Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (60 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: rituximabfailurepatientpatientseffective
  Phrases that lowered it: effectevaluate theto evaluateefficacymale
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2/3 (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 7 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 22.4% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 96.9% (raises risk) · Drug's FDA history
• Maximum age: 18 (raises risk) · Who can join
• Minimum age: 2 (lowers risk) · Who can join
• Blinding: double (raises risk) · Design
• Sponsor's past trials: 16 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 9035 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome NCT02438982 · started 2015 · scored riskier than 50% of active trials completed
• Rituximab for Idiopathic Nephrotic Syndrome NCT04494438 · started 2013 · scored riskier than 50% of active trials completed
• Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome NCT04783675 · started 2021 · scored riskier than 54% of active trials completed
• Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) NCT00981838 · started 2009 · scored riskier than 66% of active trials completed
• Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome NCT02394119 · started 2015 · scored riskier than 46% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.